This company has been marked as potentially delisted and may not be actively trading. NASDAQ:JUNS Jupiter Neurosciences (JUNS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesInsider TradesShort InterestTrendsBuy This Stock About Jupiter Neurosciences Stock (NASDAQ:JUNS) Get Jupiter Neurosciences alerts:Sign Up Key Stats Today's Range$1.38▼$1.6750-Day Range N/A52-Week Range N/AVolume486,767 shsAverage Volume140,895 shsMarket Capitalization$55.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company Overview Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida. Read More Jupiter Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreJUNS MarketRank™: Jupiter Neurosciences scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Jupiter Neurosciences.Read more about Jupiter Neurosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Jupiter Neurosciences are expected to decrease in the coming year, from ($0.06) to ($0.11) per share.Price to Book Value per Share RatioJupiter Neurosciences has a P/B Ratio of 12.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.28% of the float of Jupiter Neurosciences has been sold short.Short Interest Ratio / Days to CoverJupiter Neurosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJupiter Neurosciences does not currently pay a dividend.Dividend GrowthJupiter Neurosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.28% of the float of Jupiter Neurosciences has been sold short.Short Interest Ratio / Days to CoverJupiter Neurosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Jupiter Neurosciences this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for JUNS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Jupiter Neurosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,751.00 in company stock and sold $0.00 in company stock.Read more about Jupiter Neurosciences' insider trading history. Receive JUNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jupiter Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JUNS Stock News HeadlinesJupiter Neurosciences names biohacker Jean Fallacara as Nugevia ambassadorSeptember 16, 2025 | msn.comJupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand AmbassadorSeptember 15, 2025 | finance.yahoo.comThe Hidden “AI Royalty” PlayMost investors are chasing AI stocks like NVIDIA… but they're missing out on an under-the-radar opportunity. This $20 stock is at the center of AI's explosive energy demand—and it's paying out 270X more in "AI Royalties" than NVIDIA.September 29 at 2:00 AM | Behind the Markets (Ad)Jupiter Neurosciences announces launch of Nugevia websiteAugust 26, 2025 | msn.comJupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity SupplementsAugust 26, 2025 | markets.businessinsider.comLongevity In A Capsule: Jupiter Neurosciences Launches First Three Supplements Under Nugevia(TM) BrandAugust 20, 2025 | theglobeandmail.comJupiter Neurosciences names Chris Webber as second Nugevia brand ambassadorAugust 19, 2025 | msn.comJupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand AmbassadorAugust 19, 2025 | globenewswire.comSee More Headlines JUNS Stock Analysis - Frequently Asked Questions How were Jupiter Neurosciences' earnings last quarter? Jupiter Neurosciences, Inc. (NASDAQ:JUNS) issued its quarterly earnings results on Monday, August, 18th. The company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). When did Jupiter Neurosciences IPO? Jupiter Neurosciences (JUNS) raised $11 million in an IPO on Tuesday, December 3rd 2024. The company issued 2,800,000 shares at a price of $4.00 per share. Dominari Securities and Revere Securities acted as the underwriters for the IPO. Company Calendar Last Earnings8/18/2025Today9/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolNASDAQ:JUNS CIK1679628 Webwww.jupiterorphan.com Phone561 406 6154FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-835.24% Return on Assets-155.10% Debt Debt-to-Equity RatioN/A Current Ratio1.07 Quick Ratio1.07 Sales & Book Value Annual Sales$230 thousand Price / Sales240.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book12.23Miscellaneous Outstanding Shares34,830,000Free FloatN/AMarket Cap$55.38 million OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:JUNS) was last updated on 9/29/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.